|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 9
|
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
|
|
Dec 21
|
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
|
|
Dec 18
|
Sanofi: Information concerning the total number of voting rights and shares - November 2023
|
|
Dec 15
|
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
|
|
Dec 15
|
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
|
|
Dec 7
|
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
|
|
Dec 7
|
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
|
|
Nov 30
|
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
|
|
Nov 27
|
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
|
|
Nov 27
|
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
|
|
Nov 2
|
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
|
|
Aug 31
|
Press Release: Sanofi announces changes to its Executive Committee
|